Endocrine_JJ Resistance_NN1 in_II Breast_NN1 Cancer_NN1 
1_MC1 ._. Introduction_NN1 
Approximately_RR 70_MC %_NNU of_IO breast_NN1 cancers_NN2 are_VBR considered_VVN estrogen_NN1 receptor_NN1 alpha_NN1 (_( ERùõº_NP1 )_) and_CC /_/ or_CC progesterone_NN1 receptor_NN1 (_( PR_NP1 )_) positive_JJ ,_, and_CC the_AT hormone_NN1 estrogen_NN1 (_( 17ùõΩ-estradiol_NN1 ,_, E2_NP1 )_) represents_VVZ the_AT primary_JJ stimulant_NN1 in_II the_AT growth_NN1 and_CC development_NN1 of_IO these_DD2 tumours_NN2 [_[ 1_MC1 ]_] ._. Thus_RR deprivation_NN1 of_IO estrogen_NN1 signalling_NN1 through_II endocrine-targeted_JJ therapy_NN1 has_VHZ become_VVN the_AT mainstay_NN1 of_IO treatment_NN1 in_II ERùõº-positive_JJ disease_NN1 ._. Despite_II the_AT benefits_NN2 ,_, endocrine_JJ therapy_NN1 resistance_NN1 eventually_RR occurs_VVZ in_II a_AT1 large_JJ number_NN1 of_IO patients_NN2 and_CC represents_VVZ a_AT1 significant_JJ issue_NN1 for_IF optimal_JJ clinical_JJ management_NN1 [_[ 2_MC ]_] ._. In_II recent_JJ years_NNT2 a_AT1 large_JJ body_NN1 of_IO work_NN1 has_VHZ focused_VVN on_II trying_VVG to_TO understand_VVI the_AT underlying_JJ mechanisms_NN2 leading_VVG to_II resistance_NN1 and_CC approaches_NN2 for_IF their_APPGE circumvention_NN1 ,_, as_II31 well_II32 as_II33 developing_VVG methods_NN2 to_TO predict_VVI which_DDQ patients_NN2 are_VBR likely_JJ to_TO develop_VVI resistance_NN1 and_CC are_VBR therefore_RR in_II31 need_II32 of_II33 additional_JJ or_CC alternative_JJ therapies_NN2 ._. While_CS numerous_JJ mechanisms_NN2 have_VH0 been_VBN proposed_VVN in_II31 addition_II32 to_II33 those_DD2 discussed_VVN in_II this_DD1 review_NN1 ,_, a_AT1 major_JJ lesson_NN1 from_II the_AT laboratory_NN1 has_VHZ been_VBN the_AT realisation_NN1 that_CST resistance_NN1 is_VBZ both_RR highly_RR complex_JJ and_CC heterogeneous_JJ and_CC it_PPH1 is_VBZ clear_JJ that_CST more_DAR work_NN1 is_VBZ needed_VVN to_TO identify_VVI and_CC improve_VVI clinical_JJ outcome_NN1 of_IO patients_NN2 with_IW ER-positive_JJ breast_NN1 cancers_NN2 ._. 
2_MC ._. Estrogen_NN1 Production_NN1 
In_II both_RR pre-_JJ and_CC postmenopausal_JJ woman_NN1 estrogen_NN1 production_NN1 occurs_VVZ locally_RR in_II the_AT normal_JJ tissues_NN2 of_IO subcutaneous_JJ fat_NN1 ,_, the_AT breast_NN1 ,_, muscle_NN1 tissue_NN1 and_CC bone_NN1 ,_, where_CS it_PPH1 is_VBZ produced_VVN by_II the_AT enzymatic_JJ conversion_NN1 of_IO androgens_NN2 (_( androstenedione_NN1 and_CC testosterone_NN1 )_) by_II aromatase_NN1 [_[ 1_MC1 ,_, 3‚Äì8_MCMC ]_] (_( Figure_NP1 1_MC1 )_) ._. Within_II breast_NN1 cancer_NN1 tissue_NN1 ,_, expression_NN1 of_IO aromatase_NN1 occurs_VVZ mainly_RR in_II fibroblasts_NN2 [_[ 9_MC ]_] ._. Residual_JJ levels_NN2 of_IO estrogen_NN1 are_VBR also_RR commonly_RR found_VVN circulating_VVG in_II the_AT blood_NN1 and_CC are_VBR around_RG 20-fold_JJ higher_JJR in_II postmenopausal_JJ women_NN2 compared_VVN with_IW premenopausal_JJ women_NN2 ,_, despite_II the_AT loss_NN1 of_IO ovarian_JJ estrogen_NN1 production_NN1 [_[ 4_MC ,_, 5_MC ,_, 10_MC ]_] ._. In_II postmenopausal_JJ women_NN2 there_EX is_VBZ a_AT1 noticeable_JJ correlation_NN1 between_II risk_NN1 of_IO breast_NN1 cancer_NN1 and_CC levels_NN2 of_IO circulating_VVG estrogen_NN1 in_II the_AT blood_NN1 plasma_NN1 [_[ 11_MC ]_] ._. Aromatase_NN1 transcription_NN1 and_CC protein_NN1 levels_NN2 have_VH0 been_VBN shown_VVN to_TO differ_VVI between_II the_AT quadrants_NN2 of_IO the_AT breast_NN1 in_II women_NN2 with_IW breast_NN1 cancer_NN1 ,_, being_VBG considerably_RR increased_JJ in_II the_AT quadrant_NN1 containing_VVG the_AT tumour_NN1 [_[ 12_MC ,_, 13_MC ]_] ._. Evidence_NN1 suggests_VVZ that_CST this_DD1 is_VBZ primarily_RR due_II21 to_II22 tumour_NN1 cell-released_JJ factors_NN2 such_II21 as_II22 prostaglandins_NN2 and_CC inflammatory_JJ cell_NN1 released_JJ cytokines_NN2 such_II21 as_II22 IL6_NP1 ,_, IL11_NP1 and_CC TNFùõº_NP1 ,_, which_DDQ enhance_VV0 the_AT activity_NN1 of_IO aromatase_NN1 in_II fibroblasts_NN2 through_II intracellular_JJ cAMP_NP1 signalling_NN1 and_CC regulation_NN1 of_IO the_AT aromatase_NN1 gene_NN1 (_( CYP19_NP1 )_) via_II an_AT1 alternative_JJ non-standard_JJ promoter_NN1 [_[ 1_MC1 ,_, 14_MC ,_, 15_MC ]_] ._. 
3_MC ._. Estrogen_NN1 Signalling_NN1 
In_II hormone-dependent_JJ cancers_NN2 ,_, estrogen_NN1 taken_VVN up_RP from_II the_AT blood_NN1 plasma_NN1 or_CC from_II local_JJ production_NN1 diffuses_VVZ into_II the_AT cancer_NN1 cell_NN1 and_CC binds_VVZ ER_NP1 ,_, thus_RR causing_VVG the_AT dissociation_NN1 of_IO 

Figure_NP1 1_MC1 :_: Diagram_NN1 showing_VVG local_JJ estrogen_NN1 production_NN1 via_II the_AT enzymatic_JJ conversion_NN1 of_IO androgens_NN2 to_II estrogen_NN1 by_II aromatase_NN1 and_CC estrogen_NN1 receptor_NN1 signalling_NN1 in_II breast_NN1 cancer_NN1 ._. Estrogen_NP1 (_( E_NP1 )_) ,_, estrogen_NN1 receptor_NN1 alpha_NN1 (_( ER_NP1 )_) ,_, estrogen_NN1 response_NN1 element_NN1 (_( ERE_NP1 )_) and_CC heat-shock_NN1 proteins_NN2 (_( HSP_NP1 )_) ._. The_AT targets_NN2 of_IO commonly_RR used_JJ endocrine_JJ therapies_NN2 in_II the_AT pathway_NN1 are_VBR shown_VVN :_: aromatase_NN1 inhibitors_NN2 (_( AI_NP1 )_) ,_, tamoxifen_NN1 (_( T_NP1 )_) and_CC fulvestrant_NN1 (_( F_NP1 )_) ._. 
heat_NN1 shock_NN1 proteins_NN2 from_II the_AT ER_NP1 molecule_NN1 ._. The_AT ligand-bound_JJ molecule_NN1 dimerises_VVZ ,_, associates_VVZ with_IW other_JJ coactivator_NN1 or_CC corepressor_NN1 proteins_NN2 and_CC subsequently_RR binds_VVZ to_II conserved_JJ estrogen_NN1 response_NN1 element_NN1 (_( ERE_NP1 )_) sequences_NN2 within_II the_AT promoter_NN1 regions_NN2 of_IO genes_NN2 over_II which_DDQ it_PPH1 exerts_VVZ transcriptional_JJ control_NN1 [_[ 1_MC1 ,_, 16_MC ]_] (_( Figure_NP1 1_MC1 )_) ._. ER_NP1 is_VBZ a_AT1 nuclear_JJ receptor_NN1 encoded_VVN by_II the_AT ESR1_NP1 gene_NN1 ;_; it_PPH1 comprises_VVZ two_MC distinct_JJ transactivation_NN1 domains_NN2 :_: activation_NN1 function_NN1 (_( AF_NP1 )_) -1_MC in_II the_AT amino-terminal_NN1 region_NN1 and_CC AF2_NP1 in_II the_AT carboxy-terminal_NN1 region_NN1 [_[ 17‚Äì19_MCMC ]_] ._. AF1_NP1 is_VBZ regulated_VVN by_II growth_NN1 factors_NN2 acting_VVG through_II the_AT MAPK_NP1 pathway_NN1 whereas_CS AF2_NP1 ,_, located_VVN in_II the_AT ligand_NN1 binding_JJ region_NN1 of_IO ER_NP1 is_VBZ activated_VVN by_II estrogen_NN1 [_[ 17_MC ,_, 20_MC ]_] ._. Full_JJ agonist_NN1 activity_NN1 requires_VVZ both_RR AF1_NP1 and_CC AF2_NP1 to_TO be_VBI active_JJ [_[ 21_MC ]_] ._. Studies_NN2 have_VH0 shown_VVN that_CST ERE_NP1 bound_JJ ER_NP1 is_VBZ ubiquitinated_VVN and_CC targeted_VVN for_IF proteosomal_JJ degradation_NN1 ,_, suggesting_VVG that_CST each_DD1 ER_NP1 molecule_NN1 is_VBZ destined_VVN for_IF only_RR one_MC1 cycle_NN1 of_IO estrogen_NN1 signalling_NN1 [_[ 22_MC ]_] ._. EREs_NP2 were_VBDR first_MD discovered_VVN flanking_VVG the_AT regions_NN2 of_IO estrogen-regulated_JJ vitellogennin_NN1 genes_NN2 in_II Xenopus_FW21 laevis_FW22 and_CC have_VH0 since_RR been_VBN found_VVN in_II the_AT promoter_NN1 regions_NN2 of_IO several_DA2 hundred_NNO human_JJ genes_NN2 ,_, with_IW a_AT1 minimum_JJ consensus_NN1 sequence_NN1 consisting_VVG of_IO a_AT1 13_MC base-pair_NN1 palindromic_JJ inverted_JJ repeat_NN1 :_: 5'-GGTCANNNTGACC-3'_FO (_( N_NP1 :_: any_DD nucleotide_NN1 )_) [_[ 23‚Äì25_MCMC ]_] ._. Some_DD EREs_NP2 have_VH0 been_VBN identified_VVN which_DDQ have_VH0 imperfect_JJ palindromic_JJ sequences_NN2 ,_, differing_VVG from_II the_AT consensus_NN1 sequence_NN1 by_II one_MC1 or_CC more_DAR nucleotides_NN2 and_CC are_VBR often_RR less_RGR responsive_JJ to_TO ligand-bound_JJ ER_NP1 than_CSN consensus_NN1 sequence_NN1 EREs_NP2 [_[ 26_MC ]_] ._. The_AT association_NN1 of_IO ligand-bound_JJ ER_NP1 with_IW EREs_NP2 is_VBZ thought_VVN to_TO be_VBI achieved_VVN via_II either_DD1 of_IO two_MC mechanisms_NN2 :_: (_( i_MC1 )_) "_" direct_JJ binding_NN1 "_" in_II which_DDQ the_AT molecule_NN1 binds_VVZ to_II the_AT EREs_NP2 and_CC associates_VVZ directly_RR with_IW coactivator_NN1 /_/ corepressor_NN1 molecules_NN2 and_CC the_AT RNA_NP1 polymerase_NN1 II_MC transcription_NN1 initiation_NN1 complex_NN1 ,_, or_CC (_( ii_MC )_) "_" tethering_NN1 "_" whereby_RRQ the_AT ligand-bound_JJ ER_NP1 does_VDZ not_XX bind_VVI DNA_NN1 but_CCB rather_RR interacts_VVZ with_IW another_DD1 DNA_NN1 bound_JJ transcription_NN1 factor_NN1 either_RR stabilising_VVG that_DD1 factor_NN1 ,_, or_CC recruiting_VVG additional_JJ cofactors_NN2 to_II the_AT complex_NN1 [_[ 27_MC ,_, 28_MC ]_] ._. The_AT latter_DA is_VBZ thought_VVN to_TO be_VBI the_AT mechanism_NN1 by_II which_DDQ ligand-bound_JJ ER_NP1 associates_VVZ with_IW transcription_NN1 factor_NN1 SP1_NP1 [_[ 27_MC ]_] ._. Via_II these_DD2 transcriptional_JJ associations_NN2 estrogen_NN1 can_VM induce_VVI proliferation_NN1 of_IO cancer_NN1 cells_NN2 which_DDQ overexpress_JJ ER_NP1 ._. It_PPH1 should_VM be_VBI noted_VVN that_CST non-ligand-bound_JJ ER_NP1 complexes_NN2 can_VM also_RR bind_VVI to_II EREs_NP2 ,_, without_IW the_AT ability_NN1 to_TO regulate_VVI gene_NN1 expression_NN1 it_PPH1 was_VBDZ thought_VVN [_[ 17_MC ,_, 29‚Äì31_MCMC ]_] however_RR ,_, recent_JJ chromatin_NN1 immunoprecipitation_NN1 sequencing_NN1 data_NN (_( ChIP-seq_NP1 )_) from_II MCF7_NP1 breast_NN1 cancer_NN1 cell_NN1 lines_NN2 suggests_VVZ that_CST endogenous_JJ ERùõº_NP1 can_VM bind_VVI DNA_NN1 in_II the_AT absence_NN1 of_IO the_AT ligand_NN1 and_CC that_CST transcripts_NN2 are_VBR produced_VVN at_II those_DD2 sites_NN2 [_[ 32_MC ]_] ._. 
Although_CS the_AT exact_JJ mechanisms_NN2 by_II which_DDQ estrogen_NN1 drives_VVZ proliferation_NN1 are_VBR yet_RR to_TO be_VBI fully_RR elucidated_VVN ,_, a_AT1 number_NN1 of_IO potential_JJ models_NN2 have_VH0 been_VBN proposed_VVN [_[ 33_MC ]_] ._. In_II normal_JJ human_JJ breast_NN1 tissue_NN1 ,_, cells_NN2 which_DDQ do_VD0 not_XX express_VVI ER_NP1 proliferate_VV0 via_II paracrine_JJ signalling_NN1 ,_, whereas_CS in_II tumours_NN2 an_AT1 autocrine_JJ action_NN1 occurs_VVZ in_II which_DDQ ER-positive_JJ cells_NN2 proliferate_VV0 [_[ 34_MC ]_] ._. It_PPH1 has_VHZ been_VBN reported_VVN that_CST estrogen_NN1 promotes_VVZ transition_NN1 through_II the_AT G1/S_NP1 phase_NN1 of_IO cell_NN1 cycle_NN1 via_II a_AT1 number_NN1 of_IO pathways_NN2 involving_VVG the_AT induction_NN1 of_IO cyclin-D1_NP1 expression_NN1 by_II ligand-bound_JJ ER_NP1 ,_, mediated_VVN by_II one_MC1 or_CC more_DAR transcription_NN1 factors_NN2 including_II :_: c-Jun_NP1 ,_, c-Fos_NP1 ,_, and_CC ATF-2_NP1 at_II the_AT AP1_NP1 promoter_NN1 site_NN1 ,_, or_CC via_II an_AT1 SP1_NP1 transcription_NN1 factor_NN1 dependent_JJ pathway_NN1 [_[ 35‚Äì41_MCMC ]_] ._. Furthermore_RR ,_, ligand-bound_JJ ER_NP1 has_VHZ also_RR been_VBN shown_VVN to_TO bind_VVI cyclin-D1_NP1 and_CC ,_, as_II a_AT1 complex_JJ ,_, regulate_VVI the_AT expression_NN1 of_IO that_DD1 gene_NN1 and_CC other_JJ downstream_JJ genes_NN2 [_[ 39_MC ,_, 42_MC ]_] ._. Cyclin-D1_NP1 subsequently_RR binds_VVZ and_CC activates_VVZ CDK4_NP1 and_CC CDK6_NP1 ,_, which_DDQ regulate_VV0 G1/S_NP1 phase_NN1 transition_NN1 through_II the_AT phosphorylation_NN1 of_IO RB1_NP1 ._. The_AT latter_DA can_VM no_RR21 longer_RR22 inhibit_VVI E2F/DP1_NP1 complexes_NN2 ,_, thus_RR allowing_VVG them_PPHO2 to_TO activate_VVI the_AT transcription_NN1 of_IO S-phase_NN1 entry_NN1 genes_NN2 such_II21 as_II22 those_DD2 encoding_VVG cyclin-E1_NP1 and_CC cyclin-A1_NP1 [_[ 35_MC ,_, 36_MC ,_, 43_MC ,_, 44_MC ]_] ._. Other_JJ studies_NN2 suggest_VV0 that_CST ligand-bound_JJ ER_NP1 may_VM promote_VVI G1/S_NP1 phase_NN1 transition_NN1 by_II induction_NN1 of_IO c-MYC_NP1 which_DDQ leads_VVZ to_II activation_NN1 of_IO CDC25A_NP1 and_CC CDK4_NP1 gene_NN1 transcription_NN1 [_[ 45‚Äì47_MCMC ]_] ._. Active_JJ CDC25A_NP1 dephosphorylates_VVZ CDK2_NP1 leading_VVG to_II the_AT inhibition_NN1 of_IO RB1_NP1 and_CC p130_NP1 and_CC transcriptional_JJ activation_NN1 of_IO E2F/DP1_NP1 complexes_NN2 which_DDQ in_II turn_NN1 upregulates_VVZ S-phase_NN1 entry_NN1 genes_NN2 [_[ 36_MC ,_, 48_MC ,_, 49_MC ]_] ._. Alternatively_RR ,_, it_PPH1 has_VHZ been_VBN proposed_VVN that_CST ER_NP1 could_VM activate_VVI G1/S_NP1 phase_NN1 transition_NN1 via_II redistribution_NN1 and_CC downregulation_NN1 of_IO p21_NP1 and_CC P27KIP1_NP1 thus_RR removing_VVG their_APPGE inhibitory_JJ control_NN1 over_II key_JJ cell_NN1 cycle_NN1 progression_NN1 proteins_NN2 such_II21 as_II22 CDK2_NP1 [_[ 49_MC ,_, 50_MC ]_] ._. It_PPH1 is_VBZ thought_VVN this_DD1 might_VM be_VBI achieved_VVN by_II ubiquitin_NN1 targeting_NN1 for_IF proteosomal_JJ degradation_NN1 or_CC by_II nuclear_JJ export_NN1 via_II membrane-bound_JJ ER_NP1 associated_VVN with_IW ERK2_NP1 and_CC CRM1_NP1 [_[ 51_MC ,_, 52_MC ]_] ._. 
4_MC ._. Endocrine_JJ Therapy_NN1 
In_II 1896_MC George_NP1 Beatson_NP1 ,_, a_AT1 Glasgow_NP1 surgeon_NN1 ,_, showed_VVD that_CST patients_NN2 with_IW advanced_JJ breast_NN1 cancer_NN1 had_VHD regression_NN1 of_IO metastatic_JJ disease_NN1 following_VVG oophorectomy_NN1 ,_, providing_VVG the_AT first_MD contemporaneous_JJ published_JJ evidence_NN1 of_IO a_AT1 link_NN1 between_II hormones_NN2 and_CC breast_NN1 cancer_NN1 ._. By_II 1937_MC Dodds_NP1 and_CC Robertson_NP1 had_VHD synthesised_VVN diethylstilboestrol_NN1 and_CC its_APPGE anti-tumour_JJ activity_NN1 was_VBDZ demonstrated_VVN although_CS its_APPGE use_NN1 was_VBDZ limited_VVN by_II severe_JJ side_NN1 effects_NN2 (_( Figure_NP1 2_MC )_) [_[ 53_MC ]_] ._. In_II 1973_MC ,_, the_AT synthetic_JJ estrogen_NN1 blocker_NN1 tamoxifen_NN1 was_VBDZ licensed_VVN for_IF use_NN1 in_II the_AT treatment_NN1 of_IO hormone-positive_JJ breast_NN1 cancer_NN1 and_CC became_VVD the_AT mainstay_NN1 of_IO endocrine_JJ therapy_NN1 for_IF the_AT next_MD 30_MC years_NNT2 [_[ 54_MC ]_] ._. Today_RT ,_, endocrine_JJ therapy_NN1 constitutes_VVZ a_AT1 major_JJ treatment_NN1 modality_NN1 in_II ER-positive_JJ breast_NN1 cancer_NN1 and_CC can_VM be_VBI used_VVN alone_RR or_CC in_II31 addition_II32 to_II33 chemotherapy_NN1 ,_, which_DDQ has_VHZ more_DAR associated_JJ toxicity_NN1 [_[ 55‚Äì58_MCMC ]_] ._. Indeed_RR ,_, studies_NN2 have_VH0 shown_VVN it_PPH1 to_TO provide_VVI more_DAR benefit_NN1 in_II the_AT adjuvant_JJ setting_NN1 in_II postmenopausal_JJ women_NN2 with_IW ER-positive_JJ breast_NN1 cancer_NN1 than_CSN doxorubicin_NN1 or_CC taxane-containing_JJ chemotherapy_NN1 [_[ 59_MC ,_, 60_MC ]_] ._. Endocrine_JJ therapies_NN2 work_VV0 by_II manipulating_VVG endocrine_JJ signalling_NN1 by_II the_AT exogenous_JJ administration_NN1 of_IO hormone_NN1 antagonists_NN2 designed_VVN to_TO inhibit_VVI the_AT biosynthesis_NN1 and_CC /_/ or_CC activity_NN1 of_IO estrogen_NN1 ._. Endocrine_JJ therapies_NN2 are_VBR considered_VVN to_TO be_VBI cytostatic_JJ rather_II21 than_II22 cytotoxic_JJ ,_, leading_VVG to_II reduced_JJ proliferation_NN1 and_CC reduction_NN1 of_IO growth_NN1 rate_NN1 [_[ 61_MC ]_] ._. At_II the_AT simplest_JJT molecular_JJ level_NN1 ,_, they_PPHS2 achieve_VV0 this_DD1 through_II the_AT arrest_NN1 of_IO cell_NN1 cycle_NN1 in_II G1/S_NP1 phase_NN1 [_[ 62_MC ]_] ._. Today_RT ,_, several_DA2 types_NN2 of_IO endocrine_JJ therapies_NN2 exist_VV0 and_CC are_VBR used_VVN commonly_RR in_II the_AT treatment_NN1 of_IO ER-positive_JJ breast_NN1 cancer_NN1 in_II postmenopausal_JJ women_NN2 ._. 
First_MD synthesised_VVN in_II the_AT 1960s_MC2 ,_, tamoxifen_NN1 is_VBZ a_AT1 selective_JJ estrogen_NN1 receptor_NN1 modulator_NN1 (_( SERM_NP1 )_) (_( Figures_NP2 1_MC1 and_CC 2_MC )_) ._. 

Figure_NP1 2_MC :_: Timeline_NN1 of_IO approval_NN1 for_IF endocrine_JJ therapy_NN1 agents_NN2 ._. 
It_PPH1 functions_VVZ by_II disrupting_VVG the_AT estrogen_NN1 signalling_NN1 pathway_NN1 by_II competitive_JJ intranuclear_JJ binding_NN1 to_II ER_NP1 ,_, causing_VVG a_AT1 conformational_JJ change_NN1 to_II the_AT subsequently_RR formed_JJ ER_NP1 dimer_NN1 involving_VVG the_AT shift_NN1 of_IO helix_NN1 12_MC into_II an_AT1 adjacent_JJ coactivator_NN1 site_NN1 (_( AF2_NP1 )_) ,_, thus_RR blocking_VVG the_AT binding_NN1 of_IO the_AT coactivator_NN1 ,_, which_DDQ significantly_RR reduces_VVZ the_AT level_NN1 of_IO estrogen-regulated_JJ gene_NN1 transcription_NN1 [_[ 21_MC ,_, 63_MC ,_, 64_MC ]_] ._. However_RR ,_, this_DD1 complex_NN1 has_VHZ been_VBN shown_VVN to_TO exhibit_VVI partial_JJ estrogen-agonist_JJ properties_NN2 due_II21 to_II22 the_AT remaining_JJ activity_NN1 of_IO AF1_NP1 [_[ 1_MC1 ,_, 21_MC ]_] ._. A_AT1 newer_JJR yet_RR similar_JJ class_NN1 of_IO endocrine_JJ therapies_NN2 also_RR exist_VV0 which_DDQ are_VBR known_VVN as_II selective_JJ estrogen_NN1 receptor_NN1 downregulators_NN2 (_( SERDs_NP2 )_) and_CC these_DD2 include_VV0 fulvestrant_NN1 ,_, which_DDQ was_VBDZ first_MD approved_VVN for_IF use_NN1 in_II 2002_MC ._. Fulvestrant_NN1 functions_VVZ to_TO downregulate_VVI ER_NP1 by_II competitive_JJ binding_NN1 to_II ER_NP1 dimers_NN2 and_CC by_II causing_VVG immobilisation_NN1 of_IO ER_NP1 in_II the_AT nuclear_JJ matrix_NN1 which_DDQ is_VBZ accompanied_VVN by_II degradation_NN1 via_II the_AT ubiquitin-proteasome_NN1 pathway_NN1 [_[ 65_MC ]_] (_( Figures_NP2 1_MC1 and_CC 2_MC )_) ._. It_PPH1 has_VHZ been_VBN shown_VVN to_TO be_VBI more_RGR potent_JJ than_CSN tamoxifen_NN1 in_RR21 vitro_RR22 and_CC does_VDZ not_XX exhibit_VVI the_AT partial_JJ estrogen-agonist_JJ properties_NN2 associated_VVN with_IW tamoxifen_NN1 in_II murine_JJ models_NN2 ._. This_DD1 is_VBZ due_II21 to_II22 the_AT fact_NN1 that_CST both_RR AF1_NP1 and_CC AF2_NP1 activities_NN2 are_VBR suppressed_VVN ,_, blocking_VVG cofactor_NN1 recruitment_NN1 at_II the_AT ERE_NP1 site_NN1 of_IO estrogen_NN1 responsive_JJ genes_NN2 [_[ 21_MC ,_, 66_MC ,_, 67_MC ]_] ._. 
Another_DD1 major_JJ group_NN1 of_IO endocrine_JJ therapies_NN2 in_II routine_JJ clinical_JJ use_NN1 are_VBR third-generation_JJ aromatase_NN1 inhibitors_NN2 (_( AIs_NP2 )_) ,_, which_DDQ comprise_VV0 two_MC drug_NN1 types_NN2 ._. Firstly_RR ,_, the_AT irreversible_JJ steroidal_JJ inhibitors_NN2 (_( type_NN1 1_MC1 )_) ,_, including_II exemestane_NN1 which_DDQ are_VBR androstenedione_NN1 analogues_NN2 and_CC secondly_RR ,_, the_AT non-steroidal_JJ inhibitors_NN2 (_( type_NN1 2_MC )_) ,_, which_DDQ include_VV0 letrozole_NN1 and_CC anastrozole_NN1 [_[ 1_MC1 ,_, 68‚Äì73_MCMC ]_] (_( Figures_NP2 1_MC1 and_CC 2_MC )_) ._. AIs_NP2 seek_VV0 to_TO disrupt_VVI estrogen_NN1 signalling_NN1 by_II either_RR :_: irreversible_JJ and_CC inactivating_JJ binding_NN1 (_( type_NN1 1_MC1 )_) ,_, or_CC reversible_JJ and_CC competitive_JJ binding_NN1 (_( type_NN1 2_MC )_) to_II the_AT aromatase_NN1 enzyme_NN1 ;_; thus_RR significantly_RR reducing_VVG local_JJ estrogen_NN1 biosynthesis_NN1 and_CC hence_RR intratumoural_JJ levels_NN2 of_IO estrogen_NN1 [_[ 1_MC1 ,_, 74‚Äì76_MCMC ]_] ._. Indeed_RR ,_, in_II the_AT adjuvant_JJ setting_NN1 ,_, letrozole_NN1 ,_, anastrozole_NN1 and_CC exemestane_NN1 have_VH0 been_VBN shown_VVN to_TO be_VBI more_RGR effective_JJ than_CSN tamoxifen_NN1 with_IW a_AT1 significant_JJ reduction_NN1 in_II the_AT rate_NN1 of_IO relapse_NN1 [_[ 73_MC ,_, 77‚Äì79_MCMC ]_] ._. Endocrine_JJ therapies_NN2 can_VM also_RR be_VBI used_VVN in_II the_AT treatment_NN1 of_IO ER-positive_JJ breast_NN1 cancer_NN1 in_II premenopausal_JJ women_NN2 where_CS their_APPGE use_NN1 is_VBZ usually_RR combined_VVN with_IW drugs_NN2 such_II21 as_II22 goserelin_NN1 (_( zoladex_NN1 )_) to_TO suppress_VVI ovarian_JJ estrogen_NN1 production_NN1 [_[ 80_MC ]_] ._. 
In_II postmenopausal_JJ women_NN2 ,_, adjuvant_JJ treatment_NN1 represents_VVZ the_AT major_JJ clinical_JJ setting_NN1 for_IF endocrine_JJ therapy_NN1 ,_, where_CS long-term_JJ adjuvant_JJ systemic_JJ treatment_NN1 is_VBZ targeted_VVN against_II micro-metastatic_JJ disease_NN1 [_[ 2_MC ]_] ._. Indeed_RR ,_, several_DA2 studies_NN2 have_VH0 reported_VVN overwhelming_JJ evidence_NN1 of_IO a_AT1 high_JJ correlation_NN1 between_II the_AT adjuvant_JJ use_NN1 of_IO endocrine_JJ therapy_NN1 and_CC reduction_NN1 in_II the_AT risk_NN1 of_IO recurrence_NN1 [_[ 81_MC ]_] ._. Endocrine_JJ therapy_NN1 can_VM also_RR have_VHI an_AT1 important_JJ role_NN1 in_II the_AT neoadjuvant_JJ setting_NN1 where_CS systemic_JJ treatment_NN1 may_VM be_VBI indicated_VVN for_IF 3_MC to_II 4_MC months_NNT2 prior_II21 to_II22 surgery_NN1 in_II postmenopausal_JJ women_NN2 with_IW large_JJ and_CC /_/ or_CC technically_RR inoperable_JJ tumours_NN2 ._. This_DD1 treatment_NN1 is_VBZ intended_VVN to_TO shrink_VVI the_AT tumour_NN1 so_CS21 that_CS22 ,_, in_II locally_RR advanced_JJ disease_NN1 surgery_NN1 becomes_VVZ possible_JJ and_CC in_II large_JJ operable_JJ breast_NN1 cancers_NN2 ,_, breast_NN1 conserving_JJ surgery_NN1 (_( BCS_NP1 )_) can_VM be_VBI performed_VVN [_[ 2_MC ,_, 56_MC ]_] ._. The_AT Immediate_JJ Preoperative_JJ Anastrozole_NP1 or_CC Combined_VVN with_IW Tamoxifen_NP1 (_( IMPACT_NP1 )_) study_NN1 was_VBDZ a_AT1 phase_NN1 3_MC clinical_JJ trial_NN1 which_DDQ showed_VVD that_CST 46_MC %_NNU of_IO 124_MC ER-positive_JJ postmenopausal_JJ women_NN2 initially_RR recommended_VVN for_IF mastectomy_NN1 became_VVD eligible_JJ for_IF BCS_NP1 following_VVG 3_MC months_NNT2 of_IO neoadjuvant_JJ anastrozole_NN1 [_[ 82_MC ]_] ._. Similar_JJ results_NN2 were_VBDR found_VVN in_II a_AT1 study_NN1 of_IO exemestane_NN1 in_II which_DDQ 85_MC %_NNU of_IO 40_MC patients_NN2 deemed_VVN unfit_JJ for_IF BCS_NP1 at_II diagnosis_NN1 became_VVD eligible_JJ following_VVG 6_MC months_NNT2 of_IO neoadjuvant_JJ therapy_NN1 [_[ 83_MC ]_] ._. Indeed_RR by_II measuring_VVG proliferation_NN1 levels_NN2 of_IO malignant_JJ cells_NN2 using_VVG the_AT expression_NN1 of_IO nuclear_JJ antigen_NN1 Ki67_NP1 ,_, studies_NN2 have_VH0 shown_VVN a_AT1 reduction_NN1 in_II proliferation_NN1 in_II approximately_RR 90_MC %_NNU of_IO ER-positive_JJ primary_JJ breast_NN1 tumours_NN2 treated_VVN with_IW and_CC responsive_JJ to_II AIs_NP2 ,_, confirming_VVG that_CST these_DD2 tumours_NN2 derive_VV0 significant_JJ proliferative_JJ stimulus_NN1 from_II estrogen_NN1 and_CC that_CST this_DD1 can_VM be_VBI potently_RR supressed_VVN by_II endocrine_JJ therapy_NN1 [_[ 84_MC ,_, 85_MC ]_] ._. Endocrine_JJ therapy_NN1 can_VM also_RR be_VBI used_VVN in_II the_AT treatment_NN1 of_IO advanced_JJ or_CC metastatic_JJ disease_NN1 to_TO prolong_VVI survival_NN1 ,_, either_RR as_II a_AT1 monotherapy_NN1 or_CC as_II part_NN1 of_IO a_AT1 sequenced_JJ treatment_NN1 regimen_NN1 with_IW chemotherapy_NN1 ,_, palliative_JJ surgery_NN1 or_CC radiotherapy_NN1 [_[ 86_MC ]_] ._. 
